Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02727361 : Role of the Striatal Cholinergic System in the Pathophysiology of Dystonia
PhasePhase 3
AgesMin: 18 Years Max: 75 Years
Eligibility
Inclusion Criteria:

- Man or woman 18 to 75 years, with health insurance

- Diagnosis of dystonia DYT1 confirmed by molecular biology (TORSINE- A gene mutation)

- Patient who stopped his anticholinergic treatment 48 hours before imaging

Exclusion Criteria:

- Patients who underwent surgery for deep brain stimulation or under cholinergic
treatment.

- Presence of a counter-indication for MRI

- Presence of a counter-indication for TEP Scan with [18F]-FEOBV

- Woman premenopausal without effective ongoing contraception (intrauterine device or
combined hormonal)

- Patient who underwent a PET examination in the previous month

- Presence of any health problem preventing travel to the imaging service of the
University Hospital

- Being under the legal guardianship of another person or being unable to provide
consent to participate

- Pregnant or breastfeeding woman
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02727361      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740